Skip to main content
PMC home page
Antimicrobial Agents and Chemotherapy logoLink to Antimicrobial Agents and Chemotherapy
. 1989 Dec;33(12):2126–2131. doi: 10.1128/aac.33.12.2126

Postinfection therapy of arbovirus infections in mice.

I P Singh 1, D H Coppenhaver 1, M Sarzotti 1, P Sriyuktasuth 1, J Poast 1, H B Levy 1, S Baron 1
PMCID: PMC172833  PMID: 2619276

Abstract

Most antiviral agents are efficacious prophylactically in vivo, and a few are efficacious for postinfection (p.i.) therapy. To explore possibilities for p.i. therapy of encephalogenic Banzi virus (BZV) and Semliki Forest virus infections in mice, we evaluated candidate antiviral therapies after development of the first clinical signs of infection. The earliest clinical indication of BZV viremia in mice is a rise in core body temperature beginning on day 3 p.i. BZV-infected mice showing elevated core body temperatures (greater than or equal to 37.3 degrees C) on days 3 and 4 p.i. were treated intraperitoneally with the interferon inducer poly(ICLC) (80 micrograms per mouse) and/or specific antiserum. Combined therapy on day 3 of a BZV infection protected over 75% of mice showing clinical evidence of viral disease before treatment. Protection against early brain infection must occur on day 4 p.i., since by that day BZV has started multiplying in the brains of the mice. Significant protection occurred with antiserum alone and increased with poly(ICLC). Similar protection was obtained during Semliki Forest virus viremia, but this infection is so rapid that the first clinical signs are reliably detectable only after viremia.

Full text

PDF
2128

Images in this article

2128Image
on p.2128
2129Image
on p.2129
2129Image
on p.2129

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. BARON S., BUCKLER C. E. PROTECTIVE EFFECT OF ANTIBODY OR ELEVATED TEMPERATURE ON INTRACEREBRAL INFECTION OF MICE WITH ENCEPHALOMYCARDITIS VIRUS. J Immunol. 1964 Jul;93:45–50. [PubMed] [Google Scholar]
  2. Buckley R. H. Immunodeficiency diseases. JAMA. 1987 Nov 27;258(20):2841–2850. [PubMed] [Google Scholar]
  3. Chirigos M. A., Welker R., Schlick E., Saito T., Ruffmann R. Vaccine adjuvant effects, and immune response, to synthetic polymers MVE and poly ICLC. Prog Clin Biol Res. 1984;161:467–479. [PubMed] [Google Scholar]
  4. Earley E., Peralta P. H., Johnson K. M. A plaque neutralization method for arboviruses. Proc Soc Exp Biol Med. 1967 Jul;125(3):741–747. doi: 10.3181/00379727-125-32194. [DOI] [PubMed] [Google Scholar]
  5. Erlendsson K., Swartz T., Dwyer J. M. Successful reversal of echovirus encephalitis in X-linked hypogammaglobulinemia by intraventricular administration of immunoglobulin. N Engl J Med. 1985 Feb 7;312(6):351–353. doi: 10.1056/NEJM198502073120605. [DOI] [PubMed] [Google Scholar]
  6. Griffin D. E., Johnson R. T. Role of the immune response in recovery from Sindbis virus encephalitis in mice. J Immunol. 1977 Mar;118(3):1070–1075. [PubMed] [Google Scholar]
  7. Kumano Y., Yamamoto M., Mori R. Protection against herpes simplex virus infection in mice by recombinant murine interferon-beta in combination with antibody. Antiviral Res. 1987 Jun;7(5):289–301. doi: 10.1016/0166-3542(87)90012-x. [DOI] [PubMed] [Google Scholar]
  8. Langford M. P., Villarreal A. L., Stanton G. J. Antibody and interferon act synergistically to inhibit enterovirus, adenovirus, and herpes simplex virus infection. Infect Immun. 1983 Jul;41(1):214–218. doi: 10.1128/iai.41.1.214-218.1983. [DOI] [PMC free article] [PubMed] [Google Scholar]
  9. Levy H. B., Baer G., Baron S., Buckler C. E., Gibbs C. J., Iadarola M. J., London W. T., Rice J. A modified polyriboinosinic-polyribocytidylic acid complex that induces interferon in primates. J Infect Dis. 1975 Oct;132(4):434–439. doi: 10.1093/infdis/132.4.434. [DOI] [PubMed] [Google Scholar]
  10. Lloyd G., Bowen E. T., Slade J. H. Physical and chemical methods of inactivating Lassa virus. Lancet. 1982 May 8;1(8280):1046–1048. doi: 10.1016/s0140-6736(82)92101-8. [DOI] [PubMed] [Google Scholar]
  11. Mease P. J., Ochs H. D., Wedgwood R. J. Successful treatment of echovirus meningoencephalitis and myositis-fasciitis with intravenous immune globulin therapy in a patient with X-linked agammaglobulinemia. N Engl J Med. 1981 May 21;304(21):1278–1281. doi: 10.1056/NEJM198105213042107. [DOI] [PubMed] [Google Scholar]
  12. Mindel A., Adler M. W., Sutherland S., Fiddian A. P. Intravenous acyclovir treatment for primary genital herpes. Lancet. 1982 Mar 27;1(8274):697–700. doi: 10.1016/s0140-6736(82)92618-6. [DOI] [PubMed] [Google Scholar]
  13. Tung A. S., Ju S. T., Sato S., Nisonoff A. Production of large amounts of antibodies in individual mice. J Immunol. 1976 Mar;116(3):676–681. [PubMed] [Google Scholar]
  14. Weiner L. S., Howell J. T., Langford M. P., Stanton G. J., Baron S., Goldblum R. M., Lord R. A., Goldman A. S. Effect of specific antibodies on chronic echovirus type 5 encephalitis in a patient with hypogammaglobulinemia. J Infect Dis. 1979 Dec;140(6):858–863. doi: 10.1093/infdis/140.6.858. [DOI] [PubMed] [Google Scholar]
  15. Whitley R. J., Alford C. A., Hirsch M. S., Schooley R. T., Luby J. P., Aoki F. Y., Hanley D., Nahmias A. J., Soong S. J. Vidarabine versus acyclovir therapy in herpes simplex encephalitis. N Engl J Med. 1986 Jan 16;314(3):144–149. doi: 10.1056/NEJM198601163140303. [DOI] [PubMed] [Google Scholar]
  16. Whitley R. J. Antiviral treatment of a serious herpes simplex infection: encephalitis. J Am Acad Dermatol. 1988 Jan;18(1 Pt 2):209–211. doi: 10.1016/s0190-9622(88)70030-4. [DOI] [PubMed] [Google Scholar]
  17. Whitley R. J., Soong S. J., Dolin R., Galasso G. J., Ch'ien L. T., Alford C. A. Adenine arabinoside therapy of biopsy-proved herpes simplex encephalitis. National Institute of Allergy and Infectious Diseases collaborative antiviral study. N Engl J Med. 1977 Aug 11;297(6):289–294. doi: 10.1056/NEJM197708112970601. [DOI] [PubMed] [Google Scholar]
  18. Wiltrout R. H., Salup R. R., Twilley T. A., Talmadge J. E. Immunomodulation of natural killer activity by polyribonucleotides. J Biol Response Mod. 1985 Oct;4(5):512–517. [PubMed] [Google Scholar]
  19. Worthington M., Baron S. Late therapy with an interferon stimulator in an arbovirus encephalitis in mice. Proc Soc Exp Biol Med. 1971 Jan;136(1):323–327. doi: 10.3181/00379727-136-35257. [DOI] [PubMed] [Google Scholar]

Articles from Antimicrobial Agents and Chemotherapy are provided here courtesy of American Society for Microbiology (ASM)

RESOURCES